Clinic
Covenant Medical Center
Covenant Medical Center was paid $4.25M by Medicaid between Jan 2018 and Dec 2024, across 165 billing codes. Its largest line is 99285, emergency room visit (most serious) — 20% of everything it billed.
33Billing provider infoCOVENANT MEDICAL CENTER
LUBBOCK, TX 79410
LUBBOCK, TX 79410
33aNPI1972517365assigned 07/28/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$4.25M
24GClaims176,756
24DCodes billed165
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#87 of 320
Median peer was paid$205K
This provider vs. median21×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,125 | $389K | |
| 2019 | 8,893 | $204K | |
| 2020 | 8,104 | $174K | |
| 2021 | 50,256 | $988K | |
| 2022 | 42,303 | $1.08M | |
| 2023 | 32,330 | $940K | |
| 2024incomplete | 22,745 | $471K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 20% | 4,746 | 4,424 | $859K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.2% | 2,870 | 2,729 | $390K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.8% | 5,250 | 5,030 | $372K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 4.3% | 2,775 | 2,701 | $182K |
| G0378 | Hospital observation service, per hour | 3.3% | 716 | 426 | $140K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.1% | 4,804 | 4,176 | $131K |
| 95813 | 3.1% | 348 | 345 | $131K | |
| 93458 | 2.6% | 75 | 73 | $112K | |
| 80053 | Comprehensive metabolic panel | 2.6% | 14,119 | 11,727 | $110K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 17,721 | 14,193 | $99K |
| 87150 | 2.1% | 1,193 | 1,175 | $87K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.0% | 182 | 177 | $87K |
153 more codes
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.6% | 1,800 | $66K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.4% | 1,313 | $61K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.4% | 1,313 | $61K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.2% | 709 | $51K |
| 88313 | 1.2% | 372 | $49K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.0% | 279 | $44K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,677 | $41K |
| 83655 | <1% | 1,454 | $38K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 959 | $37K |
| 88342 | <1% | 287 | $37K | |
| 86780 | <1% | 1,787 | $35K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,408 | $34K |
| 80050 | General health panel | <1% | 743 | $34K |
| 80061 | Lipid panel | <1% | 2,234 | $34K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,899 | $31K |
| 87660 | <1% | 910 | $31K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,145 | $31K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,023 | $29K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 611 | $29K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,726 | $28K |
| 96376 | <1% | 1,361 | $28K | |
| 87480 | <1% | 968 | $27K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 738 | $26K |
| 84702 | <1% | 1,210 | $26K | |
| 95957 | <1% | 262 | $25K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,370 | $24K |
| 87510 | <1% | 972 | $23K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,316 | $21K |
| 87340 | <1% | 1,244 | $20K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,417 | $19K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,282 | $19K |
| J3490 | Unclassified drugs | <1% | 1,196 | $19K |
| CP007 | <1% | 276 | $19K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 230 | $19K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 589 | $18K |
| 0352U | <1% | 860 | $18K | |
| 86850 | <1% | 1,284 | $17K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 618 | $16K |
| 84703 | <1% | 2,124 | $15K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,011 | $15K |
| 0353U | <1% | 499 | $14K | |
| 84439 | <1% | 1,729 | $14K | |
| 84484 | <1% | 2,914 | $14K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,989 | $14K |
| 86762 | <1% | 589 | $14K | |
| 86803 | <1% | 535 | $13K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,002 | $11K |
| 82784 | <1% | 750 | $8K | |
| 85730 | <1% | 1,932 | $8K | |
| 82785 | <1% | 237 | $8K | |
| 85610 | <1% | 2,775 | $8K | |
| 82962 | <1% | 6,744 | $8K | |
| C1769 | Guide wire | <1% | 215 | $7K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 44 | $6K |
| 85027 | <1% | 1,334 | $6K | |
| 83690 | <1% | 1,354 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,209 | $6K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,833 | $6K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,479 | $6K |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,484 | $6K |
| 82950 | <1% | 760 | $6K | |
| 83880 | <1% | 1,000 | $6K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 106 | $5K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 96 | $5K |
| 86900 | <1% | 1,190 | $5K | |
| 81001 | <1% | 2,697 | $5K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 257 | $5K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 976 | $5K |
| 86901 | <1% | 1,180 | $5K | |
| 80047 | <1% | 398 | $4K | |
| 83735 | <1% | 1,252 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 449 | $4K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,315 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 353 | $4K |
| 99152 | <1% | 236 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,889 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 839 | $3K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 158 | $3K |
| 81025 | <1% | 384 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 41 | $3K |
| 87077 | <1% | 1,131 | $3K | |
| 87797 | <1% | 63 | $3K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 159 | $3K |
| 87186 | <1% | 1,005 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 876 | $2K |
| 93976 | <1% | 25 | $2K | |
| 81003 | <1% | 1,490 | $2K | |
| 82150 | <1% | 322 | $2K | |
| A9270 | Non-covered item or service | <1% | 3,426 | $2K |
| 0240U | <1% | 203 | $2K | |
| 87070 | <1% | 176 | $2K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 13 | $2K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 34 | $2K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 17 | $2K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 109 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 730 | $2K |
| 94010 | <1% | 37 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 552 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 518 | $1K |
| 81000 | <1% | 416 | $1K | |
| 83789 | <1% | 37 | $1K | |
| 76937 | <1% | 68 | $1K | |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 103 | $1K |
| 83525 | <1% | 47 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 527 | $1K |
| 83605 | <1% | 373 | $1K | |
| 86800 | <1% | 52 | $1K | |
| 83516 | <1% | 67 | $1K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 293 | $963.97 |
| 86376 | <1% | 50 | $929.72 | |
| 87634 | <1% | 12 | $875.12 | |
| 85018 | <1% | 208 | $792.12 | |
| 85014 | <1% | 255 | $787.45 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 217 | $775.20 |
| 87081 | <1% | 54 | $769.24 | |
| 82607 | <1% | 108 | $760.77 | |
| 82746 | <1% | 82 | $713.51 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 286 | $688.21 |
| 87040 | <1% | 164 | $599.21 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 74 | $594.10 |
| 83615 | <1% | 58 | $557.62 | |
| 84132 | <1% | 246 | $478.52 | |
| 82951 | <1% | 17 | $463.20 | |
| 80076 | <1% | 47 | $445.41 | |
| 86140 | <1% | 137 | $426.46 | |
| 84550 | <1% | 58 | $417.92 | |
| 97161 | <1% | 27 | $390.07 | |
| 84305 | <1% | 12 | $333.86 | |
| 82728 | <1% | 12 | $320.69 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 12 | $205.43 |
| 82575 | <1% | 12 | $152.00 | |
| 82952 | <1% | 17 | $140.95 | |
| 85007 | <1% | 47 | $125.53 | |
| 84156 | <1% | 16 | $80.85 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 64 | $80.47 |
| 83721 | <1% | 18 | $79.37 | |
| J1815 | Injection, insulin, per 5 units | <1% | 107 | $64.36 |
| 80179 | <1% | 13 | $49.22 | |
| 80143 | <1% | 13 | $49.22 | |
| 80164 | <1% | 87 | $48.93 | |
| 82077 | <1% | 15 | $46.92 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 36 | $44.22 |
| 85652 | <1% | 14 | $39.34 | |
| 80069 | <1% | 38 | $29.08 | |
| 87088 | <1% | 29 | $26.06 | |
| 80177 | <1% | 18 | $20.59 | |
| 87205 | <1% | 16 | $16.44 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 12 | $14.16 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 14 | $11.92 |
| 82570 | <1% | 14 | $10.81 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 2,126 | $0.00 |
| 82805 | 0% | 13 | $0.00 | |
| 84100 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY OF ENROLLMENTS)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.